NEW ORLEANS — Maribavir, an antiviral once deemed promising for cytomegalovirus (CMV) infection but discarded after a negative phase 3 trial, has been shown to be effective in treatment-resistant and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback